Insider trade

Officer sold ~$5.15M of ABBV shares in the open market

Traded Feb 25, 2026 · Filed Feb 27, 2026

AbbVieABBV

~$5.15M
Reported value · 22K sh @ $230.00: 38K
Holds after · shares reported: +14.6%
stock since the trade · S&P 500 +10.2%, $226.92 → $259.93 on Oct 1

Why it stands out

AbbVie's GC AND SECRETARY sold $5.15M of AbbVie shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 25, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 27, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$5,147,630

Shares × reported transaction price

Timing vs results

21 days after results of Feb 4, 2026, 37 days before results of Apr 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $226.92 on Feb 25, 2026, 33% above its 52-week low and 7% below its high, after a 3% rise over the previous 30 trading days

52-week range $170.16 (Apr 21, 2025) to $244.38 (Oct 1, 2025), 76% of the way up, from 251 adjusted closes. 30 trading days earlier: $220.04 on Jan 12, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Venclexta on Feb 19, 2026, 6 days before this trade.

New use approved (efficacy supplement). Active ingredient: Venetoclax. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.9%	-1.2%	-1.7%
30 days	-8.2%	-4.5%	-3.7%
90 days	-9.1%	+10.5%	-19.6%
180 days	+9.5%	+11.8%	-2.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0001951400-26-000004
Filed / recorded: Feb 27, 2026, 10:00 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: AbbVie Inc.
Issuer CIK: 1551152
Ticker: ABBV
Reporting person: Perry C Siatis
Relationship: Officer
Officer title: EVP, GC AND SECRETARY
Security: Common Stock, $0.01 par value
Table: Non-derivative (Table I)
Transaction date: Feb 25, 2026
Transaction code: S
Shares / units: 22,381
Price per share: $230.00
Acquired / disposed: Disposed (D)
Shares owned after: 38,137
Ownership form: Direct
Amendment: No

Around the same time

7mo ago

2,108Shares · @ $232.08

Routine share withholding; mechanical by default.

Why it stands out Official record

Officer sold7mo ago

~$1.22MReported value · 5,230 sh @ $233.56

7,884 → 2,654 shares held−66% of their stake

AbbVie's SVP, Controller sold $1.22M of AbbVie shares. Nobody planned it ahead of time.

Why it stands out Official record

7mo ago

1,594Shares · @ $232.08

Routine share withholding; mechanical by default.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Around the same time

2,108Shares · @ $232.08

~$1.22MReported value · 5,230 sh @ $233.56

1,594Shares · @ $232.08

Most active this month